Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Wegovy Pill by Ro: January 2026 consumer analysis examines oral GLP-1 legitimacy, Novo Nordisk integration, and no-insurance cash-pay options.
-
New capabilities enable Teladoc Health’s care teams to address a broader spectrum of health needs, delivering more value in virtual urgent care visits
-
Direct Meds reviews best GLP-1 weight loss shot prescription pathways for 2026 as oral semaglutide and injectable formats expand patient access.
-
Ipamorelin vs Sermorelin 2026 analysis compares growth hormone peptide mechanisms, regulatory status, and prescription telehealth access pathways.
-
MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs
Analysis examines MEDVi's compounded GLP-1 semaglutide telehealth model, FDA compounding framework, and prescription weight loss trends for 2026.
-
NAD+ research examines cellular aging as telehealth expands peptide therapy access — RenuviaRX platform model, pricing, and oversight revealed.
-
Best peptides for skin care: Consumer analysis examines injectable Glutathione tripeptide vs topical delivery for January 2026 wellness planning.
-
January 2026 consumer analysis compares oral Wegovy, compounded sublingual semaglutide, and tirzepatide drops across pricing and access formats.
-
Industry analysis compares FDA-approved Wegovy pricing from $149 oral to Ro's $199 injectable as telehealth access expands for 2026.
-
Analysis examines best tirzepatide access pathways for 2026 including FDA regulatory changes, insurance coverage shifts, and cash-pay options.